Tuberculosis was the world’s top infectious disease killer last year
Tuberculosis has emerged as the world’s top infectious disease with about 8.2 million people newly diagnosed with the illness last year — the.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Tuberculosis has emerged as the world’s top infectious disease with about 8.2 million people newly diagnosed with the illness last year — the.
The World Health Organization has for the first time activated its emergency health network in eight countries affected by the mpox outbreak, including.
Israel has passed a law to ban the UN relief agency, UNRWA, from operating in the country after it earlier accused its employees.
Researchers have found genomic variants in one-third of people from the West African countries of Ghana and Nigeria that significantly increase the risk.
By Aparna S October 29, 2024: Imposter syndrome is a psychological phenomenon that affects many high-achieving individuals, often leading them to downplay their.
Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise.
AbbVie Inc. will acquire Aliada Therapeutics, a biotechnology company focused on developing drugs to treat diseases of the central nervous system such as.
AstraZeneca Plc’s drug Fasenra got approval from the European Union regulator for treating adult patients with a rare inflammation of blood vessels.
GSK Plc., will invest $800 million in its manufacturing facility in the US — the largest investment to date in the country — to.
A clinical-stage US gene-editing company, Precision BioSciences, got approval from the Eastern European country of Moldova to start an in vivo human trial.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com